Karlin Daniel
Chief Medical Officer
Karlin Daniel has filed 7 SEC Form 4 filings (7 transaction rows) across 2 companies, including DFTX, MNMD, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Karlin Daniel is listed as Chief Medical Officer at Definium Therapeutics, Inc. Inside the rolling window, Karlin Daniel reported no open-market purchases and 4 open-market sales totaling $749K in DFTX and MNMD. The largest disclosed transaction in the window is a sale of 10,035 DFTX shares on Jun 25, 2026, worth $452K.
Companies traded
Other insiders at DFTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$749K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Karlin Daniel made?
Karlin Daniel has filed 7 SEC Form 4 filings (7 transaction rows) across 2 companies, including DFTX, MNMD since 2025.
Which companies does Karlin Daniel trade?
Karlin Daniel has filed SEC Form 4 disclosures for 2 companies, including DFTX, MNMD.
When was Karlin Daniel's most recent SEC Form 4 filing?
Karlin Daniel's most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Karlin Daniel's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Karlin Daniel is listed as Chief Medical Officer.
What is Karlin Daniel's total buy and sell value in the current window?
Inside the rolling retention window, Karlin Daniel bought $0 and sold $749K based on SEC Form 4 filings.
What was Karlin Daniel's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,035 DFTX shares on 2026-06-25, worth $452K, per SEC Form 4 filings.